66 search results for: pediatric
Explore the Global Burden of Pediatric AD (PEDISTAD)
This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.
SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?
Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
The PEDISTAD Survey: Assessing the Burden of Atopic Dermatitis in the Global Pediatric Population
An interactive tool used to explore the global burden of atopic dermatitis in children and adolescents.
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia
Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.
Association of Younger Age of Onset With Persistence of AD
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
Current systemic therapies have been shown to induce remission in a subset of AD patients
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.
